News
Job Offer : ITEOS Therapeutics is looking for Research Scientist
We are looking for: Iteos Position Research Scientist March 2013 (full-time …
Promethera Biosciences opens the French part of its clinical trial in cell therapy
Promethera successfully administers Promethera® HepaStem in an adolescent suffering from …
Management Buy-Out at Telemis, a spin-off of the Université catholique de Louvain (« UCL ») and leader in medical imaging
Louvain-la-Neuve, October 10, 2012, Nivelinvest and Sopartec announced the disposal …
SORIN Acquires UCL Spin-off NeuroTECH
Louvain-la-Neuve, Belgium- November 12th, 2012 – SORIN, a global medical …
MSC Software Acquires UCL Spin-off e-Xstream
Louvain-la-Neuve, Belgium- September 27th, 2012 – MSC Software, one of …
VIVES – Louvain Technology Fund participates in second round funding of DelfMEMS, a French company active in the RF MEMS devices
Louvain-la-Neuve (Belgium), January 14th, 2013 VIVES – Louvain Technology Fund, …
Sopartec is looking for a CEO with a strong track record in the biotech industry
For the creation of a new spin-off company based on the development of novel cell-based therapies, SOPARTEC SA (www.sopartec.com), Member of the Louvain Technology Transfer Office, is looking for A CHIEF EXECUTIVE OFFICER with a strong track record in the biotech/biomedical industry
Neurotech s.a. Announces European CE Mark Approval for the ADNS-300 System to Treat Refractory Epilepsy.
Louvain la Neuve, Belgium, June 5, 2012 —Neurotech s.a. (www.neurotech-int.eu) a Belgium based developer and manufacturer of neurostimulation devices, announces that it has obtained the European CE Mark for its ADNS-300 system dedicated to the treatment of refractory epilepsy. The surgically implanted ADNS-300 system delivers mild electrical pulses to the vagus nerve in the neck. Operating as a pacemaker, it produces stimulation towards the brain.
Promethera Biosciences treats first patients with Promethera® HepaStem
Mont-Saint-Guibert, Belgium, May 14 2012 – Promethera Biosciences, a Belgian biotechnology Company developing Promethera® HepaStem, a cell-based therapy for the treatment of liver-based metabolic diseases including Crigler-Najjar Syndrome and Urea Cycle Disorders, today announces it has treated its first two patients with its innovative treatment based on allogeneic adult liver stem cell technology (HepaStem). These patients were treated and are followed at the Cliniques
Universitaires Saint-Luc (Brussels, Belgium).
Vives subscribes to a € 6 million capital increase to support GreenWatt growth
Vives – Louvain Technology Fund subscribes jointly with historic shareholders and new investors Gimv Agri+, RWE Innogy Ventures and SRIW to a € 6 million capital increase of GreenWatt S.A.
With this capital increase, GreenWatt S.A. will accelerate its international development in the waste-to-energy business.
Launch of VivesII, the largest european university technology fund
Louvain-la-Neuve, 28 September 2011 – The Université catholique de Louvain (UCL) and Sopartec, its technology transfer
company, today announced the launch of Vives II. The first financing round, which brings together a dozen investors,
amounts to €43 million, making Vives II the largest European investment fund ever initiated by a university.
Click on the link below to download our press release in a PDF format.
